Evaluation of the Oncomine Comprehensive Assay Plus for comprehensive genomic profiling including homologous recombination deficiency assessment.

Precision oncology research continues to explore the utility of targeted therapies and immunotherapies. As we gain a deeper understanding of the molecular mechanisms of tumor biology, comprehensive genomic profiling (CGP) is critical to help drive insights into advancing the future of personalized medicine. In this webinar, learn how the Ion Torrent™ Oncomine™ Comprehensive Assay Plus, an amplicon-based next-generation sequencing (NGS) assay, can be used to simultaneously analyze a broad range of biomarkers, including homologous recombination deficiency (HRD), in one test to maximize insights into the underlying oncogenic drivers in timely manner.

Webinar Learning Objectives

Factors to consider when evaluating NGS technologies for CGP
The relevance of CGP to detect variants across tumor sample types
The importance of genomic signatures like HRD testing in ovarian cancer research samples and how it can be measured

For Research Use Only. Not for use in diagnostic procedures.

© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified

Annarita Destro PhD

Head of Molecular Pathology Department, Humanitas Research Hospital, Milan, Italy

Appearances